A growing global health threat—antimicrobial resistance—is reaching a critical point, but new advances in artificial intelligence could offer a powerful solution.
Speaking at WIRED Health 2026, Ara Darzi highlighted how AI is transforming the fight against drug-resistant infections.
A Rapidly Escalating Global Crisis
Antimicrobial resistance (AMR) is already responsible for more than a million deaths each year worldwide, with millions more linked to complications from resistant infections.
The issue is driven by:
- Overuse and misuse of antibiotics
- Slow development of new drugs
- Bacteria evolving resistance over time
Experts warn that without action, the problem could worsen dramatically in the coming decades.
Why Current Treatments Are Failing
Traditional diagnostic methods can take 2 to 3 days to identify infections.
In critical cases like sepsis:
- Every hour of delay increases the risk of death
- Doctors often rely on trial-and-error treatment
- Incorrect antibiotics can worsen resistance
This delay is one of the biggest challenges in modern medicine.
AI Is Changing the Game
According to Darzi, AI-powered tools are already delivering breakthroughs:
- Over 99% diagnostic accuracy without complex labs
- Ability to identify resistance patterns in hours instead of years
- Faster and more precise treatment decisions
In one example, AI uncovered resistance mechanisms in just 48 hours, a process that previously took nearly a decade.
Accelerating Drug Discovery
Beyond diagnostics, AI is also speeding up the development of new antibiotics.
- Screening billions of molecular combinations in days
- Designing entirely new drug compounds
- Running automated experiments around the clock
These capabilities could help overcome the current slowdown in antibiotic innovation.
The Real Problem: Economics, Not Technology
Despite technological progress, pharmaceutical companies are pulling back from antibiotic development.
Why?
- Antibiotics are used sparingly to prevent resistance
- Lower usage means lower profits
- Traditional business models don’t support long-term investment
Experts argue that the biggest barrier is no longer science—but incentives.
New Business Models Emerging
To address this, governments are testing new approaches:
- “Subscription-style” payment systems (like Netflix models)
- Fixed payments for access to antibiotics
- Incentives not tied to sales volume
These models aim to make antibiotic development financially viable again.
Final Thoughts
The fight against antimicrobial resistance is at a turning point.
The tools to solve the crisis already exist
The challenge now is global coordination and investment
As Darzi emphasized, the future of medicine may depend not on innovation—but on how quickly the world chooses to act.
